| Age at onset | 59.5 years (20 - 84) | n | % |
| Sex | Male | 3 | 10% |
| Female | 27 | 90% | |
| Race | Caucasian | 18 | 60% |
| African American | 11 | 37% | |
| Unknown | 1 | 3% | |
| Ulcer location | Toes | 3 | 10% |
| Feet | 4 | 13% | |
| Ankle | 7 | 23% | |
| Leg | 11 | 37% | |
| Thigh | 2 | 7% | |
| ≥3 sites | 5 | 17% | |
| Ssc Type | Limited | 19 | 63% |
| Diffuse | 4 | 13% | |
| Overlap syndrome/NOS | 7 | 23% | |
| Hypercoagulable state | abnormal antiphospholipid antibodies | 4 | 13% |
| Clinical evidence | 1 | 3% | |
| Comorbidities | Raynaud’s | 27 | 90% |
| Digital ulcers | 16 | 53% | |
| Osteolysis | 9 | 30% | |
| Digit loss | 7 | 23% | |
| Peripheral neuropathy | 18 | 60% | |
| Diabetes | 2 | 7% | |
| Hypertension | 20 | 67% | |
| Vascular disease | Venous | 9 | 30% |
| Arterial | 11 | 37% | |
| Venous and Arterial | 2 | 7% | |
| Tobacco use | Current | 4 | 13% |
| Former | 6 | 20% | |
| Never | 20 | 67% | |
| Medications | PD5 inhibitor | 11 | 37% |
| ERA | 7 | 23% | |
| ACE/ARB | 8 | 27% | |
| Anticoagulation | 3 | 10% | |
| Antiplatelet | 18 | 60% | |
| Calcium channel blocker | 25 | 83% | |
| Pentoxyphylline | 8 | 27% | |
| IV prostacyclin analog | 2 | 7% | |
| Immunosuppressant use for Ssc at time of ulcer | Yes | 20 | 67% |
| No | 10 | 33% |